Our aim is to compare the effects of a panel of selective COX-1 (acetylsalicylic acid or ASA), COX-2 (meloxicam or MEL), 5-LOX (MK-886 and AA-861), 12-LOX (baicalein) and 15-LOX (PD-146176) inhibitors and their in vitro synergies with two classic antineoplastic drugs used in melanoma treatment: dacarbazine (or DTIC) and temozolomide (or TMZ) (Figure 1) in the same cell line and conditions. Here, ALOX15 is linked to melanoma.